Beam Therapeutics, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -0.80%332.160.0%$4510.00m
NVAXNovavax, Inc. -0.93%164.7179.4%$740.93m
BNTXBioNTech SE 0.91%263.470.0%$711.23m
AMGNAmgen, Inc. 1.27%205.701.4%$545.06m
REGNRegeneron Pharmaceuticals, Inc. 1.93%553.942.7%$427.63m
SNSSSunesis Pharmaceuticals, Inc. -2.72%6.090.7%$425.71m
GILDGilead Sciences, Inc. 1.50%66.891.0%$413.96m
CCXIChemoCentryx, Inc. 5.80%34.312.9%$407.53m
ILMNIllumina, Inc. 0.20%411.363.3%$375.42m
XLRNAcceleron Pharma, Inc. 0.25%173.445.3%$363.37m
VRTXVertex Pharmaceuticals, Inc. 1.76%183.991.9%$262.82m
BIIBBiogen, Inc. -0.12%269.401.7%$233.37m
OCGNOcugen, Inc. 3.26%8.530.0%$184.38m
XENEXenon Pharmaceuticals, Inc. -0.16%30.670.4%$171.47m
CRSPCRISPR Therapeutics AG 4.20%100.260.6%$160.70m

Company Profile

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.